Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
2026-03-25 16:56:46 ET
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its shares leaped skyward on the news. By the end of the day, they had risen by almost 20% in value.
Corcept announced that the U.S. Food and Drug Administration (FDA) approved its Lifyorli, in combination with the chemotherapy drug nab-paclitaxel, for the treatment of the platinum-resistant stages of ovarian, fallopian tube, and primary peritoneal cancer. The approval covers adults who have previously been administered one to three prior systemic treatment regimens.
Image source: Getty Images.
NASDAQ: CORT
CORT Trading
-2.43% G/L:
$37.815 Last:
238,685 Volume:
$38.09 Open:
